Genialis has been supporting the California Pacific Medical Center, Research Institute (CPMCRI) with the identification of variants in circulating cell-free DNA samples since early 2019. Recently, a paper titled Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience has been published in the Journal of Personalised Medicine (DOI) which Genialis co-authored. It describes the Institute’s experience with this method in general and a particular brand of targeted DNA panels in particular. It provides an inventory of the data collected to date and describes a handful of case reports in which this analysis has led to improved monitoring of a disease or better clinical decisions.

Share this story, choose your platform!